GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzex Neuropharma Inc (OTCPK:TRRI) » Definitions » EPS (Diluted)

Alzex Neuropharma (Alzex Neuropharma) EPS (Diluted) : $ (TTM As of . 20)


View and export this data going back to 2011. Start your Free Trial

What is Alzex Neuropharma EPS (Diluted)?

Alzex Neuropharma's Earnings per Share (Diluted) for the three months ended in . 20 was $0.00.

Alzex Neuropharma's EPS (Basic) for the three months ended in . 20 was $0.00.

Alzex Neuropharma's EPS without NRI for the three months ended in . 20 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Alzex Neuropharma EPS (Diluted) Historical Data

The historical data trend for Alzex Neuropharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzex Neuropharma EPS (Diluted) Chart

Alzex Neuropharma Annual Data
Trend
EPS (Diluted)

Alzex Neuropharma Quarterly Data
EPS (Diluted)

Competitive Comparison of Alzex Neuropharma's EPS (Diluted)

For the Biotechnology subindustry, Alzex Neuropharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzex Neuropharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzex Neuropharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Alzex Neuropharma's PE Ratio falls into.



Alzex Neuropharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Alzex Neuropharma's Diluted EPS for the fiscal year that ended in . 20 is calculated as

Diluted EPS (A: . 20 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-)/0
=

Alzex Neuropharma's Diluted EPS for the quarter that ended in . 20 is calculated as



Alzex Neuropharma  (OTCPK:TRRI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Alzex Neuropharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Alzex Neuropharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzex Neuropharma (Alzex Neuropharma) Business Description

Traded in Other Exchanges
N/A
Address
8275 South Eastern Avenue, Suite 200-168, Las Vegas, NV, USA, 89123
Alzex Neuropharma Inc is a development-stage biopharmaceutical company that has developed and patented precision therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquees) a French academic engineering and research institute.

Alzex Neuropharma (Alzex Neuropharma) Headlines

No Headlines